First US Patient Dosed With Investigational Stem Cell Therapy IMS001 for MS
The first US patient has been dosed with an investigational stem cell therapy called IMS001, for multiple sclerosis (MS), developed by ImStem Biotechnology.
ImStem Files Opening Brief of Appeal to The U.S. Court of Appeals for The Federal Circuit Concerning Stem Cell Patents
ImStem Announces First US Multiple Sclerosis Patient Has Been Dosed with its IMS001
ImStem Biotechnology today announces the dosing of the first US multiple sclerosis patient with its lead investigational drug candidate IMS001 at the Shepherd Center in Atlanta, GA.